The intranasal drug delivery devices market size is poised to grow by $ 5.26 billion by 2032 from $ 1.49 Billion in 2022, exhibiting a CAGR of 13.5% during the forecast period 2023-2032.
The main objective of this report is to define, describe, and forecast the global market by types, application, manufacturers, and regions. The report provides detailed information about the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the market. The report aims to strategically analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market. The report also attempts to forecast the market size of the 5 main regions: North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA), and Latin America. It strategically profiles the key market players and comprehensively analyzes their core competencies. It also tracks and analyzes competitive developments, such as joint ventures, mergers and acquisitions, new developments, and Research and Development (R&D) activities, in market.
Get a Sample: https://www.precedenceresearch.com/sample/1253
COVID-19 Impact
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the electric vehicle fuel cell market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Major companies operating in this area
- Johnson & Johnson, Inc.
- Aptar Pharma Group
- GlaxoSmithKline Plc
- Aegis Therapeutics LLC
- H&T Presspart Manufacturing Ltd.
- AstraZeneca Plc
- Becton, Dickinson and Company
- Novartis AG
- Teleflex Incorporated
- Vectura Group Plc.
Market Segmentation
By System
- Metered Dose
- Multi-Dose Systems
- Unit-Dose Systems
By Container
- Non-Pressurized Containers
- Pressurized Containers
By Application
- Chronic Obstructive Pulmonary Disease (COPD)
- Rhinitis
- Cystic Fibrosis
- Nasal Congestion
- Asthma
- Others
By End User
- Ambulatory Surgical Centers
- Clinics
- Hospitals
- Others
By Geography
North America
- U.S.
- Canada
Europe
- Germany
- France
- United Kingdom
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
Major highlights of Report:
- Figures related to sales volume, market remuneration, and segmental shares
- Featuring market dynamics
- Growth prospects and expansion graph
- PROCON study of direct & indirect sales channels
- Profiles of prominent traders, dealer, and distributors in the industry
Geographical landscape: North America, Europe, Asia-Pacific, South America, Middle East and Africa
- Industry forecasts based on region and at country level
- Data about sales volume recorded, industry share held, and profit margins amassed
- Overall remuneration and estimated growth rate for each regional market
Major Key Points Covered in Report:
Executive Summary: It includes key trends of the electric vehicle fuel cell market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the electric vehicle fuel cell market based on production and revenue.
Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.
Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Electric vehicle fuel cell market.
Market Segments: This part of the report discusses product, application and other segments of the electric vehicle fuel cell market based on market share, CAGR, market size, and various other factors.
Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Intranasal Drug Delivery Devices Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
Chapter 5. COVID 19 Impact on Intranasal Drug Delivery Devices Market
5.1. Covid-19: Intranasal Drug Delivery Devices Industry Impact
5.2. Intranasal Drug Delivery Devices Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Intranasal Drug Delivery Devices Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Intranasal Drug Delivery Devices Market Players to deal with Covid-19 Pandemic Scenario
Chapter 6. Intranasal Drug Delivery Devices Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. High prevalence of cardiovascular diseases
6.1.1.2. Patent expiration of popular drugs, increased cases of cancer and diabetes
6.1.2. Market Restraints
6.1.2.1. Complications Associated with the Overuse
6.1.3. Market Opportunities
6.1.3.1. Growing adoption of self-administration practices
6.1.3.2. Technological advancements
Chapter 7. Global Intranasal Drug Delivery Devices Market: Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Intranasal Drug Delivery Devices Market Revenue by Market Players (2016 -2019)
7.1.1.2. Intranasal Drug Delivery Devices Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, System Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users
Chapter 8. Global Intranasal Drug Delivery Devices Market, By System
8.1. Intranasal Drug Delivery Devices Market, by System, 2016-2027
8.1.1. Metered Dose
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Multi-Dose Systems
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Unit-Dose Systems
8.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Intranasal Drug Delivery Devices Market, By Container
9.1. Intranasal Drug Delivery Devices Market, by Container, 2016-2027
9.1.1. Non-Pressurized Containers
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Pressurized Containers
9.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 10. Global Intranasal Drug Delivery Devices Market, By Application
10.1. Intranasal Drug Delivery Devices Market, by Application, 2016-2027
10.1.1. Chronic Obstructive Pulmonary Disease (COPD)
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Rhinitis
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Cystic Fibrosis
10.1.3.1. Market Revenue and Forecast (2016-2027)
10.1.4. Nasal Congestion
10.1.4.1. Market Revenue and Forecast (2016-2027)
10.1.5. Asthma
10.1.5.1. Market Revenue and Forecast (2016-2027)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2016-2027)
Chapter 11. Global Intranasal Drug Delivery Devices Market, By End User
11.1. Intranasal Drug Delivery Devices Market, by End User, 2016-2027
11.1.1. Ambulatory Surgical Centers
11.1.1.1. Market Revenue and Forecast (2016-2027)
11.1.2. Clinics
11.1.2.1. Market Revenue and Forecast (2016-2027)
11.1.3. Hospitals
11.1.3.1. Market Revenue and Forecast (2016-2027)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2016-2027)
Chapter 12. Global Intranasal Drug Delivery DevicesMarket, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue Forecast by System(2016-2027)
12.1.2. Market Revenue Forecast by Container(2016-2027)
12.1.3. Market Revenue Forecast by Application(2016-2027)
12.1.4. Market Revenue Forecast by End User (2016-2027)
12.1.5. U.S
12.1.5.1. Market Revenue Forecast (2016-2027)
12.1.6. Canada
12.1.6.1. Market Revenue Forecast (2016-2027)
12.2. Europe
12.2.1. Market Revenue Forecast by System (2016-2027)
12.2.2. Market Revenue Forecast by Container (2016-2027)
12.2.3. Market Revenue Forecast by Application (2016-2027)
12.2.4. Market Revenue Forecast by End User (2016-2027)
12.2.5. UK
12.2.5.1. Market Revenue Forecast (2016-2027)
12.2.6. Germany
12.2.6.1. Market Revenue Forecast (2016-2027)
12.2.7. France
12.2.7.1. Market Revenue Forecast (2016-2027)
12.2.8. Rest of EU
12.2.8.1. Market Revenue Forecast (2016-2027)
12.3. Asia Pacific (APAC)
12.3.1. Market Revenue Forecast by System (2016-2027)
12.3.2. Market Revenue Forecast by Container (2016-2027)
12.3.3. Market Revenue Forecast by Application (2016-2027)
12.3.4. Market Revenue Forecast by End User (2016-2027)
12.3.5. China
12.3.5.1. Market Revenue Forecast (2016-2027)
12.3.6. India
12.3.6.1. Market Revenue Forecast (2016-2027)
12.3.7. Japan
12.3.7.1. Market Revenue Forecast (2016-2027)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue Forecast (2016-2027)
12.4. LATAM
12.4.1. Market Revenue Forecast by System (2016-2027)
12.4.2. Market Revenue Forecast by Container (2016-2027)
12.4.3. Market Revenue Forecast by Application (2016-2027)
12.4.4. Market Revenue Forecast by End User (2016-2027)
12.4.5. Brazil
12.4.5.1. Market Revenue Forecast (2016-2027)
12.4.6. Rest of LATAM
12.4.6.1. Market Revenue Forecast (2016-2027)
12.5. Middle East and Africa (MEA)
12.5.1. Market Revenue Forecast by System (2016-2027)
12.5.2. Market Revenue Forecast by Container (2016-2027)
12.5.3. Market Revenue Forecast by Application (2016-2027)
12.5.4. Market Revenue Forecast by End User (2016-2027)
12.5.5. GCC
12.5.5.1. Market Revenue Forecast (2016-2027)
12.5.6. North Africa
12.5.6.1. Market Revenue Forecast (2016-2027)
12.5.7. South Africa
12.5.7.1. Market Revenue Forecast (2016-2027)
12.5.8. Rest of MEA
12.5.8.1. Market Revenue Forecast (2016-2027)
Chapter 13. Company Profiles
13.1. Johnson & Johnson, Inc.
13.1.1. Company Overview, Business Information, Regional Presence
13.1.2. Product Portfolio Analysis
13.1.2.1. Product Details, Specification, Application
13.1.3. Revenue, Price, and Gross Margin (2015-2020)
13.1.4. Recent Developments and Strategies
13.2. Aptar Pharma Group
13.2.1. Company Overview, Business Information, Regional Presence
13.2.2. Product Portfolio Analysis
13.2.2.1. Product Details, Specification, Application
13.2.3. Revenue, Price, and Gross Margin (2015-2020)
13.2.4. Recent Developments and Strategies
13.3. GlaxoSmithKline Plc
13.3.1. Company Overview, Business Information, Regional Presence
13.3.2. Product Portfolio Analysis
13.3.2.1. Product Details, Specification, Application
13.3.3. Revenue, Price, and Gross Margin (2015-2020)
13.3.4. Recent Developments and Strategies
13.4. Aegis Therapeutics LLC
13.4.1. Company Overview, Business Information, Regional Presence
13.4.2. Product Portfolio Analysis
13.4.2.1. Product Details, Specification, Application
13.4.3. Revenue, Price, and Gross Margin (2015-2020)
13.4.4. Recent Developments and Strategies
13.5. H&T Presspart Manufacturing Ltd.
13.5.1. Company Overview, Business Information, Regional Presence
13.5.2. Product Portfolio Analysis
13.5.2.1. Product Details, Specification, Application
13.5.3. Revenue, Price, and Gross Margin (2015-2020)
13.5.4. Recent Developments and Strategies
13.6. AstraZeneca Plc
13.6.1. Company Overview, Business Information, Regional Presence
13.6.2. Product Portfolio Analysis
13.6.2.1. Product Details, Specification, Application
13.6.3. Revenue, Price, and Gross Margin (2015-2020)
13.6.4. Recent Developments and Strategies
13.7. Becton, Dickinson and Company
13.7.1. Company Overview, Business Information, Regional Presence
13.7.2. Product Portfolio Analysis
13.7.2.1. Product Details, Specification, Application
13.7.3. Revenue, Price, and Gross Margin (2015-2020)
13.7.4. Recent Developments and Strategies
13.8. Novartis AG
13.8.1. Company Overview, Business Information, Regional Presence
13.8.2. Product Portfolio Analysis
13.8.2.1. Product Details, Specification, Application
13.8.3. Revenue, Price, and Gross Margin (2015-2020)
13.8.4. Recent Developments and Strategies
13.9. Teleflex Incorporated
13.9.1. Company Overview, Business Information, Regional Presence
13.9.2. Product Portfolio Analysis
13.9.2.1. Product Details, Specification, Application
13.9.3. Revenue, Price, and Gross Margin (2015-2020)
13.9.4. Recent Developments and Strategies
13.10. Vectura Group Plc.
13.10.1. Company Overview, Business Information, Regional Presence
13.10.2. Product Portfolio Analysis
13.10.2.1. Product Details, Specification, Application
13.10.3. Revenue, Price, and Gross Margin (2015-2020)
13.10.4. Recent Developments and Strategies
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments